STVN logo

Stevanato Group S.p.A. Stock Price

NYSE:STVN Community·US$6.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

STVN Share Price Performance

US$24.58
6.28 (34.32%)
31.9% undervalued intrinsic discount
US$36.07
Fair Value
US$24.58
6.28 (34.32%)
33.6% undervalued intrinsic discount
US$37.00
Fair Value
Price US$24.58
AnalystHighTarget US$37.00
AnalystConsensusTarget US$28.35
AnalystLowTarget US$23.00

STVN Community Narratives

AnalystHighTarget·
Fair Value US$36.07 31.9% undervalued intrinsic discount

Automation And Biologics Adoption Will Transform Injectable Solutions

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$28.62 14.1% undervalued intrinsic discount

US Onshoring And Rising Biologics Demand Will Reshape Drug Delivery

1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value US$23 6.9% overvalued intrinsic discount

Rising Regulatory Costs And Local Rivalry Will Compress Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent STVN News & Updates

Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings

Sep 22
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results

Stevanato: Expansion In Italy And The U.S. Will Pave The Way

Jul 22

Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt

Jun 23
Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)

May 19
A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)

Stevanato Group S.p.A. Key Details

€1.1b

Revenue

€820.7m

Cost of Revenue

€324.4m

Gross Profit

€189.8m

Other Expenses

€134.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.49
Gross Margin
28.33%
Net Profit Margin
11.75%
Debt/Equity Ratio
28.8%

Stevanato Group S.p.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
2 Rewards

About STVN

Founded
1949
Employees
5521
CEO
Franco Stevanato
WebsiteView website
www.stevanatogroup.com

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Italian Market Performance

  • 7 Days: 1.2%
  • 3 Months: 5.9%
  • 1 Year: 26.4%
  • Year to Date: 23.2%
Over the last 7 days, the market has risen 1.2%, driven by gains of 4.8% in the Consumer Discretionary sector. The market is up 26% over the last 12 months. As for the next few years, earnings are expected to grow by 9.9% per annum. Market details ›